AGA Medical Wraps Up Septal Occluder Trial Enrollment For ASD Repair
This article was originally published in The Gray Sheet
Executive SummaryAGA Medical plans to submit initial data in early 1999 supporting a premarket approval application for its Amplatzer septal occluder for treatment of atrial septal defects. Over the next two to three months, the company expects to complete the control arm of the pivotal study, a prospective surgical cohort.
You may also be interested in...
Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.
After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.